BNP Paribas Asset Management
PCVX icon

BNP Paribas Asset Management’s Vaxcyte PCVX Stock Holding History

BNP Paribas Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Sell
1,961
-248
-11% -$13.5K ﹤0.01% 1522
2026
Q1 		$128K Buy
2,209
+573
+35% +$31.1K ﹤0.01% 1443
2025
Q4 		$75K Buy
+1,636
New +$73.2K ﹤0.01% 1548
2025
Q3 		– Sell
-1,218
Closed -$40K – 2025
2025
Q2 		$40K Buy
+1,218
New +$39.9K ﹤0.01% 1224

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BNP Paribas Asset Management's PCVX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Vaxcyte (PCVX) stake by 11% in Q2 2026, selling an estimated $13.5K and leaving 1,961 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #1522.

BNP Paribas Asset Management first reported a position in PCVX in Q2 2025 and has held it in 4 quarters since. The position peaked at $128K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • BNP Paribas Asset Management held 1,961 shares of Vaxcyte worth $114K as of Q2 2026.
  • BNP Paribas Asset Management sold 248 Vaxcyte shares in Q2 2026, an estimated $13.5K.
  • Vaxcyte made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1522 holding.
  • BNP Paribas Asset Management first reported a position in Vaxcyte in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Asset Management's Vaxcyte position peaked at $128K in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.